Selective serotonin reuptake inhibitors (SSRIs) are associated with a high incidence of impotence. Paroxetine is an extensively used SSRI that has been shown to impair erectile function in patients, to induce erectile dysfunction and to inhibit nitric oxide synthase (NOS) activity and NO production in animal models. NO is a key mediator of penile erection. Vardenafil is a type 5 phosphodiesterase inhibitor that potentiates NO-mediated responses in isolated trabecular smooth muscle and penile erection in men in clinical trials. The aim of this study was to evaluate the effects of vardenafil on the impairment of erectile responses produced by paroxetine in the rat model. Application of cavernosal nerve electrical stimulation (CNES) produced frequency-related intracavernosal pressure (ICP) increases, which were inhibited by the NOS inhibitor N G -nitro-l-arginine (0.3 mg/kg) and potentiated by vardenafil (0.3 mg/kg). Acute paroxetine treatment (10 mg/kg) significantly reduced ICP-responses to CNES. This inhibition was completely reversed by vardenafil (0.3 mg/kg) administration. The results show that the erectile dysfunction induced by paroxetine in rats can be effectively treated with vardenafil, suggesting that the use of this compound could be a reasonable therapeutic approach to treating erectile dysfunction associated with SSRI administration.
Introduction
The treatment of depression and other psychiatric disorders with selective serotonin reuptake inhibitors (SSRIs) is associated with a high incidence of sexual dysfunction, reaching incidence rates above 50% in some studies. 1 Orgasm delay, anorgasmia, delayed ejaculation and impotence are commonly observed in men and women under SSRI treatment. 2 Furthermore, some degree of erectile dysfunction secondary to SSRI administration appears in more than 40% of men. 3 Sexual alterations usually disappear when the treatment is interrupted. 4 Paroxetine is a representative compound of the SSRI class that has been extensively used in the clinical practice 5 and, like other compounds of its class, has been reported to induce sexual dysfunction. [1] [2] [3] 6 It is able to inhibit in vitro and in vivo the synthesis of nitric oxide (NO) 7 which is a key mediator of penile smooth muscle relaxation and penile erection. 8, 9 We have previously reported that paroxetine impairs erectile responses to cavernosal nerve stimulation in rats when administered either chronically or acutely. 10 Vardenafil is a potent and selective type 5 phosphodiesterase (PDE5) inhibitor that enhances NO-mediated relaxation of human corpus cavernosum and NO-induced rabbit penile erection. 11 The aim of this work was to evaluate the effects of the treatment with vardenafil on the erectile dysfunction induced by acute administration of paroxetine in rats.
Methods

Erectile responses to cavernosal nerve stimulation in anaesthetized rats
Studies were performed in accordance with the Declaration of Helsinki and with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the National Institutes of Health. Male Sprague-Dawley rats were anaesthetized with ketamine (60 mg/kg). The surgical procedure consisted of dissection and isolation of the right cavernous nerve through an abdominal midline incision and exposure of penile crura through a transverse perineal incision. Intracavernosal pressure (ICP) measurements were accomplished by insertion into the right crus of a 23-gauge needle connected to a disposable pressure transducer (Abbott, Sligo, Ireland) and a data acquisition system (ADInstruments, Castle Hill, Australia). Right carotid artery and left external jugular vein were catheterized for constant blood pressure measurement and saline or drug infusion, respectively. Electrical stimulation was applied by a delicate platinum bipolar hook electrode connected to a stimulator and current amplifier (Cibertec, Madrid, Spain). Parameters of electrical stimulation consisted of pulses with a duration of 1 ms and 1.5 mA of current intensity for 1 min. Frequency-response curves were performed by applying stimulation at 1 and 3 Hz with an interval of 3 min between both frequencies.
For evaluation of acute effects of the treatments on erectile responses, a control stimulation at 1 and 3 Hz was performed and, after a stabilization period, paroxetine (10 mg/kg), vardenafil (0.3 mg/kg) or both dissolved in 20% 2-hydroxypropyl-b-cyclodextrin (HPbCD) or the vehicle alone were intravenously administered. The stimulation was repeated at 60 min from the time of the administration.
Data are expressed as the area under the curve (AUC) of the ICP increase to pelvic nerve stimulation normalized by the mean arterial pressure (MAP) value determined at the time of each stimulation.
Drugs and materials
Ketamine hydrochloride was obtained from ParkeDavis (Barcelona, Spain). Paroxetine hydrochloride was provided by Forest Laboratories (New York, USA). N G -nitro-l-arginine (l-NNA) and HPbCD were obtained from Sigma Chemical Co. (St Louis, MO, USA). Vardenafil was provided by Bayer AG (Wuppertal, Germany).
Results
Intravenous administration of 20% HPbCD (vehicle) did not modify blood pressure or heart rate in anaesthetized rats, while infusion of paroxetine (10 
Discussion
Relaxation of trabecular smooth muscle is needed to achieve and maintain penile erection. 12 NO is a key mediator of penile smooth muscle relaxation, 8, 9 which is released by nitrergic nerves within the trabecular and penile arterial tissues as well as the endothelia that line the lacunar spaces and the intima of penile arteries. 9 Inhibitors of NOS inhibit penile erection elicited by the stimulation of the pelvic nerves. 13 Indeed, in our model, the intravenous administration of an NOS inhibitor caused a reduction of erectile responses. NO activates guanylate cyclase leading to elevation of intracellular levels of cyclic GMP (cGMP) and penile smooth muscle relaxation. 8, 9 PDE5 is the key regulatory enzyme of cGMP levels in corpus cavernosum. 14 Vardenafil is a selective PDE5 inhibitor that has been shown to potentiate NO-mediated relaxation of human corpus cavernosum by increasing cGMP accumulation in this tissue 11 and enhances erectile function in patients. 15 Consistent with this mechanism of action, vardenafil potentiated erectile responses to electrical stimulation of the cavernosal nerve in our animal model.
It has been previously demonstrated that the SSRI paroxetine inhibits NOS activity in hamster brain and depressed patients. 7 The interference of paroxetine with the catalytic activity of NOS could be related to the reported ability of this agent, shared by other SSRIs, such as fluoxetine and fluvoxamine, to inhibit, potently, the activity of cytochrome P450 isozymes, 16 which are structurally related to NOS. Furthermore, we have demonstrated that paroxetine reduces erectile responses to cavernosal nerve stimulation in anaesthetized rats, likely because of interference with NO production. 10 Here we confirm that the acute intravenous administration of the SSRI paroxetine impairs erectile responses to cavernosal stimulation in rats. In this model, vardenafil is able to reverse the erectile dysfunction provoked by paroxetine, maintaining normal responses in the rats treated with both drugs. These observations are consistent with the hypothesis that paroxetine impairs the NO/ cGMP pathway, probably at the level of NO production, 10 while vardenafil potentiates this pathway by Vardenafil reverses erectile dysfunction by SSRI J Angulo et al enhancing cGMP accumulation. The ability of vardenafil to return erectile response to normal (ie pretreatment levels) in the presence of paroxetine suggests that PDE5 inhibition is able to compensate for the deficiency in the NO/cGMP pathway induced by the SSRI. The existence of adverse events affecting sexual function in patients undergoing treatment with SSRIs is a common clinical observation. 1, 3, 6 Since there are a large number of patients undergoing SSRI treatment, the prevention of sexual side effects becomes an important therapeutic objective, both to improve the quality of life and prevent discontinuation of treatment because of its sexual side effects. One possibility would be the use of SSRIs with fewer sexual side effects, as previously reported. 10 On the other hand, treatment with PDE5 inhibitors could alleviate the sexual dysfunction secondary to SSRI administration, as reported in case reports in male patients 17 and preliminary clinical trials in females treated with sildenafil. 18 This concept is supported by the results of the present study, which demonstrates that treatment with the new PDE5 inhibitor, vardenafil is able to reverse completely the erectile dysfunction experimentally induced by paroxetine administration, providing a rationale for the use of PDE5 inhibitors in the treatment of erectile dysfunction secondary to treatment with SSRIs.
